舒泰神(300204.SZ):2019年淨利預降70%-85%
格隆匯1月23日丨舒泰神(300204.SZ)披露2019年度業績預告,公司預計2019年1-12月歸屬於上市公司股東的淨利潤為約2010.88萬元~4021.75萬元,同比下降70%-85%。業績變動原因如下:
1、公司在研項目穩步快速推進,研發費用持續增長。其中在研項目凝血因子X激活劑(國家I類治療用生物製品,項目名稱:注射用STSP-0601)於2019年05月申報新藥臨牀試驗取得受理通知書,2019年07月獲得《臨牀試驗通知書》,2019年12月藥物I期臨牀試驗信息於國家藥品監督管理局藥物臨牀試驗登記與信息公示平台公示,2020年01月第一例受試者入組;子公司三諾佳邑及舒泰神申報的關於治療乙型肝炎病毒感染相關疾病的基因藥物(國家I類治療用生物製品,項目名稱:STSG-0002注射液)於2019年06月取得新藥臨牀試驗受理通知書,2019年09月獲得《臨牀試驗通知書》,2019年12月藥物I期臨牀試驗信息於國家藥品監督管理局藥物臨牀試驗登記與信息公示平台公示;此外,公司及子公司德豐瑞2018年申報的單克隆抗體藥物(國家I類治療用生物製品,項目名稱:BDB-001注射液)於2018年07月11日獲得《藥物臨牀試驗批件》,2019年10月第一例受試者入組,目前處於I期臨牀試驗階段(詳見公司在創業板指定信息披露網站巨潮資訊網(www.cninfo.com.cn)發佈的相關公告)。
2、報告期內,公司產品舒泰清銷售收入繼續實現快速且穩健的增長;蘇肽生銷售收入較去年同期下降較多。
3、預計2019年度公司非經常性損益約為1366.06萬元,主要原因系報告期內公司及子公司獲得的與收益相關的政府補助所致,具體數據以2019年年度報告中披露數據為準。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.